Sara R. Fagerlie, PhD, CHCP
@cancercommunicator.com
Founder of CancerCommunicator.com - Dedicated to improving the care of patients with cancer through news and clinician education.
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
October 17, 2025 at 7:08 PM
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
October 17, 2025 at 9:35 AM
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
September 12, 2025 at 8:10 PM
What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...
August 31, 2025 at 3:23 PM
"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...
ODAC voted against the overall benefit-risk of belantamab mafodotin combinations (BVd and BPd) not disputing the drug's efficacy, but citing toxicity and a missed opportunity to optimize dose along with inadequate enrollment of the US population. #MMSM #FDA www.youtube.com/live/CLhBI3U...
July 18, 2025 at 3:09 PM
ODAC voted against the overall benefit-risk of belantamab mafodotin combinations (BVd and BPd) not disputing the drug's efficacy, but citing toxicity and a missed opportunity to optimize dose along with inadequate enrollment of the US population. #MMSM #FDA www.youtube.com/live/CLhBI3U...
The latest episode of Oncology Unscripted with John Marshall is live! We recorded this one at #ASCO25. Enjoy! clinicalcaresolutions.net/activities/o...
June 12, 2025 at 6:58 PM
The latest episode of Oncology Unscripted with John Marshall is live! We recorded this one at #ASCO25. Enjoy! clinicalcaresolutions.net/activities/o...
Ph 3 VERIFY study (part1a) presented by kuykendallmd.bsky.social during the #ASCO25 plenary: weekly rusfertide improved clinical response, maintained Hct <45%, and reduced phlebotomy need vs pbo w/ ⬆️ QOL in pts with polycythemia vera. Benefit across subgroups. New SOC #cansky #oncsky #hemesky #PV
June 1, 2025 at 7:45 PM
#NIVOPOSTOP adjuvant nivolumab+radiochemotherapy vs radiochemotherapy alone in resected locally advanced #HNSCC <75y at high risk of relapse: 3y DFS 63.1% vs 51.5% HR=0.76 P=.034 #cansky #oncsky #medsky #asco25 #ascoplenary
June 1, 2025 at 7:04 PM
#NIVOPOSTOP adjuvant nivolumab+radiochemotherapy vs radiochemotherapy alone in resected locally advanced #HNSCC <75y at high risk of relapse: 3y DFS 63.1% vs 51.5% HR=0.76 P=.034 #cansky #oncsky #medsky #asco25 #ascoplenary
#ATOMIC mFOLFOX6 vs mFOLFOX6+atezolizumab in stage III dMMR colon cancer yields improved DFS (3y 76.6% vs 86.4%) #ascoplenary #asco25 #cansky #oncsky
June 1, 2025 at 6:39 PM
#ATOMIC mFOLFOX6 vs mFOLFOX6+atezolizumab in stage III dMMR colon cancer yields improved DFS (3y 76.6% vs 86.4%) #ascoplenary #asco25 #cansky #oncsky
This Isn’t Just About Harvard-It’s About All of Us. "You can understand why this is threatening to what is truly been special about United States education, and that is the freedom of speech, the freedom of thought, the challenging of each other..." bit.ly/3YSjZFi #medsky #academicsky
May 22, 2025 at 2:40 PM
This Isn’t Just About Harvard-It’s About All of Us. "You can understand why this is threatening to what is truly been special about United States education, and that is the freedom of speech, the freedom of thought, the challenging of each other..." bit.ly/3YSjZFi #medsky #academicsky
SURMOUNT-5: for obesity but w/o diabetes, tirzepatide superior to semaglutide wrt reduction in body weight and waist circumference at wk 72. N=751 meant % weight change -20.2% vs -13.7% (P<.001). High rates of GI AEs w/ both agents. #medsky #obesitymedicine
May 15, 2025 at 2:29 PM
SURMOUNT-5: for obesity but w/o diabetes, tirzepatide superior to semaglutide wrt reduction in body weight and waist circumference at wk 72. N=751 meant % weight change -20.2% vs -13.7% (P<.001). High rates of GI AEs w/ both agents. #medsky #obesitymedicine
Boston hospitals will be hit hard from the government's retaliation against Harvard. These 5 hospitals collectively received >$1.56 billion in NIH in 2024. This is not okay. Harvard and affiliates to excellent cancer research and patients will be impacted @medsky www.thecrimson.com/article/2025...
April 15, 2025 at 2:11 PM
Boston hospitals will be hit hard from the government's retaliation against Harvard. These 5 hospitals collectively received >$1.56 billion in NIH in 2024. This is not okay. Harvard and affiliates to excellent cancer research and patients will be impacted @medsky www.thecrimson.com/article/2025...
I made this the other day
February 28, 2025 at 4:16 AM
I made this the other day
#Alliance25 is in the books. It was so much fun to present with these smart and lovely humans! #Medsky #AIethics
January 11, 2025 at 4:32 PM
#Alliance25 is in the books. It was so much fun to present with these smart and lovely humans! #Medsky #AIethics
What an amazing presentation by Dr Sheppard at #Alliance25. #AI is not pulling data out of thin air, it echos what it's been given and presents it as fact which has some serious and real consequences #Medsky #CME
January 9, 2025 at 3:37 PM
What an amazing presentation by Dr Sheppard at #Alliance25. #AI is not pulling data out of thin air, it echos what it's been given and presents it as fact which has some serious and real consequences #Medsky #CME